Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Marco A Chacon
AddedMar 31, 2024
UpdatedMay 31, 2026
Marco A Chacon

Marco A Chacon

Co-Founder, Irazu Bio

CrunchbaseLinkedIn

Marco A Chacon's Career

Irazu Bio
Irazu Bio

Baltimore, MD, US

Co-Founder
Irazu Oncology
Irazu Oncology

Baltimore, MD, US

Founder
Center for Breakthrough Medicines
Center for Breakthrough Medicines

King of Prussia, PA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Marco A Chacon's Career

Irazu Bio
Irazu Bio
Seed$50k22019Baltimore, MD, US
Co-Founder

Leadership at Irazu Bio

Marco ChacónMarco ChacónCo-Founder

Similar to Irazu Bio

Curie.BioCurie.BioBoston, MA, USDrug Developmentest. 2022Curie.BioBoston, MA, US · est. 2022

Curie.Bio: A seed-stage venture firm specializing in drug-focused services for founders.

Series B26
iQure PharmaiQure PharmaWilmington, DE, USTherapeuticsest. 2019iQure PharmaWilmington, DE, US · est. 2019

iQure Pharma: Innovating new therapeutics by bridging academic research and the pharma industry.

Pre-Seed · $1.9M6
Enspire BioEnspire BioLos Angeles, CA, USDrug Discoveryest. 2017Enspire BioLos Angeles, CA, US · est. 2017

Enspire Bio, a drug discovery firm, transforms academic research into therapeutic development for various diseases.

Seed · $3.2M7
Celdara MedicalCeldara MedicalLebanon, TN, USMedical Innovationsest. 2008Celdara MedicalLebanon, TN, US · est. 2008

Celdara Medical transforms early-stage academic innovations into high-potential medical companies, bridging discovery and profitability.

Seed · $1.7M28
Irazu Oncology
Irazu Oncology
Seed$2.6M52022Baltimore, MD, US
Founder

Similar to Irazu Oncology

CancervaxCancervaxSanta Barbara, CA, USCancer Treatmentest. 2021CancervaxSanta Barbara, CA, US · est. 2021

CancerVAX Biotech: Santa Barbara-based medical firm innovating universal cancer treatments.

Seed · $500k13
EpiVax OncologyEpiVax OncologyProvidence, RI, USCancer Vaccinesest. 2017EpiVax OncologyProvidence, RI, US · est. 2017

EpiVax Oncology: A US-based biotech firm specializing in precision cancer immunotherapy vaccines.

Pre-Seed · $1.5M5
Istari OncologyIstari OncologyMorrisville, NC, USCancer Treatment, Immunotherapyest. 2014Istari OncologyMorrisville, NC, US · est. 2014

Istari Oncology, Inc.: A clinical-stage biotech firm innovating in immuno-oncology for diverse tumor treatments.

Series D · $48.5M37
Adventris PharmaceuticalsAdventris PharmaceuticalsSan Francisco, CA, USCancer Vaccinesest. 2022Adventris PharmaceuticalsSan Francisco, CA, US · est. 2022

Adventris Pharmaceuticals, a San Francisco-based firm, specializes in developing cancer vaccines.

Pre-Seed · $500k6
Center for Breakthrough Medicines
Center for Breakthrough Medicines
Late Stage Private$350M3272020King of Prussia, PA, US
Board Member· Board

Leadership at Center for Breakthrough Medicines

Audrey GreenbergAudrey GreenbergCo-Founder
Joerg AhlgrimmJoerg AhlgrimmCEO
Audrey G.Audrey G.Co-Founder

Similar to Center for Breakthrough Medicines

VintaBioVintaBioPhiladelphia, PA, USViral Vectorsest. 2020VintaBioPhiladelphia, PA, US · est. 2020

VintaBio: Expert CDMO provider for viral vectors, advancing cell and gene therapy manufacturing.

Series D · $64M15
Kincell BioKincell BioGainesville, FL, USCell Therapy, Manufacturingest. 2023Kincell BioGainesville, FL, US · est. 2023

Florida-based Kincell streamlines development and manufacturing of immune cell therapies.

Series A · $36M44
Stemedica Cell TechnologiesStemedica Cell TechnologiesSan Diego, CA, USCell Therapy, Therapeuticsest. 2005Stemedica Cell TechnologiesSan Diego, CA, US · est. 2005

Stemedica Cell Technologies: Developing and commercializing cell and protein therapies for medical needs.

Series B · $67M175
ElevateBioElevateBioCambridge, MA, USCell Therapy, Gene Therapyest. 2017ElevateBioCambridge, MA, US · est. 2017

ElevateBio, a cell and gene therapy firm, develops and commercializes transformative medicines, swiftly turning R&D into viable therapies.

Series D · $1.2B375

People Similar to Marco A Chacon

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailJuan JaenJuan JaenCo-Founder · Arcus BiosciencesJuan AguilarJuan AguilarCo-Founder · Invariantes FundJeffrey WayJeffrey WayCo-Founder · 64x BioLarry ZeitlinLarry ZeitlinCo-Founder · Mapp BiopharmaceuticalVincent A. AlessiVincent A. AlessiCo-Founder · Covaron Advanced MaterialsJonathan MuñozJonathan MuñozFounder · Rocojo